BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 26743031)

  • 1. Metabolism: Totally addicted to NAD(.).
    Shipman L
    Nat Rev Cancer; 2016 Feb; 16(2):70. PubMed ID: 26743031
    [No Abstract]   [Full Text] [Related]  

  • 2. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.
    Tateishi K; Wakimoto H; Iafrate AJ; Tanaka S; Loebel F; Lelic N; Wiederschain D; Bedel O; Deng G; Zhang B; He T; Shi X; Gerszten RE; Zhang Y; Yeh JJ; Curry WT; Zhao D; Sundaram S; Nigim F; Koerner MVA; Ho Q; Fisher DE; Roider EM; Kemeny LV; Samuels Y; Flaherty KT; Batchelor TT; Chi AS; Cahill DP
    Cancer Cell; 2015 Dec; 28(6):773-784. PubMed ID: 26678339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NAD as a genotype-specific drug target.
    Mei SC; Brenner C
    Chem Biol; 2013 Nov; 20(11):1307-8. PubMed ID: 24267273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase.
    Zhang LY; Liu LY; Qie LL; Ling KN; Xu LH; Wang F; Fang SH; Lu YB; Hu H; Wei EQ; Zhang WP
    Eur J Pharmacol; 2012 Jan; 674(2-3):163-70. PubMed ID: 22119381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nicotinamide phosphoribosyltransferase inhibitor APO866 induces C6 glioblastoma cell death via autophagy.
    Yang P; Zhang L; Shi QJ; Lu YB; Wu M; Wei EQ; Zhang WP
    Pharmazie; 2015 Oct; 70(10):650-5. PubMed ID: 26601421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Could NAMPT inhibition become a potential treatment option in hepatocellular carcinoma?
    Garten A; Schuster S; Penke M
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):289-291. PubMed ID: 28271737
    [No Abstract]   [Full Text] [Related]  

  • 7. [Key role of nicotinamide phosphoribosyltransferase (NAMPT) and NAD metabolism in the transition of melanoma cells to an invasive and drug-resistant phenotype].
    Bertolotto C; Ohanna M; Ballotti R
    Med Sci (Paris); 2018 Dec; 34(12):1025-1028. PubMed ID: 30623759
    [No Abstract]   [Full Text] [Related]  

  • 8. The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in
    Tateishi K; Higuchi F; Miller JJ; Koerner MVA; Lelic N; Shankar GM; Tanaka S; Fisher DE; Batchelor TT; Iafrate AJ; Wakimoto H; Chi AS; Cahill DP
    Cancer Res; 2017 Aug; 77(15):4102-4115. PubMed ID: 28625978
    [No Abstract]   [Full Text] [Related]  

  • 9. Apoptosis induced by NAD depletion is inhibited by KN-93 in a CaMKII-independent manner.
    Takeuchi M; Yamamoto T
    Exp Cell Res; 2015 Jul; 335(1):62-7. PubMed ID: 26024774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
    Chen H; Wang S; Zhang H; Nice EC; Huang C
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
    Curtin ML; Heyman HR; Clark RF; Sorensen BK; Doherty GA; Hansen TM; Frey RR; Sarris KA; Aguirre AL; Shrestha A; Tu N; Woller K; Pliushchev MA; Sweis RF; Cheng M; Wilsbacher JL; Kovar PJ; Guo J; Cheng D; Longenecker KL; Raich D; Korepanova AV; Soni NB; Algire MA; Richardson PL; Marin VL; Badagnani I; Vasudevan A; Buchanan FG; Maag D; Chiang GG; Tse C; Michaelides MR
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3317-3325. PubMed ID: 28610984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
    Bai J; Liao C; Liu Y; Qin X; Chen J; Qiu Y; Qin D; Li Z; Tu ZC; Jiang S
    J Med Chem; 2016 Jun; 59(12):5766-79. PubMed ID: 27224875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
    Zheng X; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Oh A; Wang W; Zak M; Wang Y; Yuen PW; Bair KW
    Bioorg Med Chem Lett; 2014 Jan; 24(1):337-43. PubMed ID: 24279990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma.
    Gujar AD; Le S; Mao DD; Dadey DY; Turski A; Sasaki Y; Aum D; Luo J; Dahiya S; Yuan L; Rich KM; Milbrandt J; Hallahan DE; Yano H; Tran DD; Kim AH
    Proc Natl Acad Sci U S A; 2016 Dec; 113(51):E8247-E8256. PubMed ID: 27930300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting NAMPT for Therapeutic Intervention in Cancer and Inflammation: Structure-Based Drug Design and Biological Screening.
    Pulla VK; Sriram DS; Soni V; Viswanadha S; Sriram D; Yogeeswari P
    Chem Biol Drug Des; 2015 Oct; 86(4):881-94. PubMed ID: 25850461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
    Dragovich PS; Zhao G; Baumeister T; Bravo B; Giannetti AM; Ho YC; Hua R; Li G; Liang X; Ma X; O'Brien T; Oh A; Skelton NJ; Wang C; Wang W; Wang Y; Xiao Y; Yuen PW; Zak M; Zhao Q; Zheng X
    Bioorg Med Chem Lett; 2014 Feb; 24(3):954-62. PubMed ID: 24433859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NAD- and NADPH-Contributing Enzymes as Therapeutic Targets in Cancer: An Overview.
    Pramono AA; Rather GM; Herman H; Lestari K; Bertino JR
    Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase.
    Oh A; Ho YC; Zak M; Liu Y; Chen X; Yuen PW; Zheng X; Liu Y; Dragovich PS; Wang W
    Chembiochem; 2014 May; 15(8):1121-30. PubMed ID: 24797455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved synthesis of MC4-PPEA and the biological evaluation of its hydroxymethyl derivative.
    Sadrerafi K; Zargham EO; Lee MW
    Bioorg Med Chem Lett; 2016 Jan; 26(2):618-621. PubMed ID: 26681512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Novel Inhibitors and Fluorescent Probe Targeting NAMPT.
    Wang X; Xu TY; Liu XZ; Zhang SL; Wang P; Li ZY; Guan YF; Wang SN; Dong GQ; Zhuo S; Le YY; Sheng CQ; Miao CY
    Sci Rep; 2015 Jul; 5():12657. PubMed ID: 26227784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.